Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 27;104(3):485–496. doi: 10.3324/haematol.2018.197749

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 6. — Knockdown of NRF2 significantly sensitizes myelodysplastic syndrome (MDS) cells to cytarabine (Ara-C) in vivo. (A) Flow cytometry showed appearance of human CD45⁺ cells in liver tumors of scramble, NRF2 and DUSP1 shRNA SKM-1 transplanted NSGS mice. (B) Liver tumors in scramble, NRF2 and DUSP1 shRNA SKM-1 transplanted NSGS mice with phosphate buffer saline (PBS) or Ara-C treatment. (C) Liver tumor volumes were significantly smaller in NRF2 or DUSP1 shRNA SKM-1 transplanted MDS mice treated with Ara-C compared with PBS. *P<0.05; **P<0.01; ***P≤0.001. g: grams.